Disease flares during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia

被引：0
|
作者：
Hampel, Paul [1 ]
Call, Timothy [2 ]
Rabe, Kari [2 ]
Ding, Wei [2 ]
Muchtar, Eli [2 ]
Kenderian, Saad [2 ]
Leis, Jose [2 ]
Witzig, Thomas [2 ]
Koehler, Amber [2 ]
Fonder, Amie [2 ]
Schwager, Susan [2 ]
Van Dyke, Daniel [2 ]
Slager, Susan [2 ]
Kay, Neil [2 ]
Parikh, Sameer [2 ]
机构：
[1] Mayo Clin, Sch Grad Med Educ, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
来源：
LEUKEMIA & LYMPHOMA | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2117
引用
收藏
页码：204 / 206
页数：3
相关论文
共 50 条
  • [31] Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia
    Hansenne, Amandine
    Camboni, Alessandra
    Van den Neste, Eric
    Bailly, Sarah
    LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 3051 - 3053
  • [32] Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
    Voshtina, Ensi
    Huang, Huiya
    Raj, Renju
    Atallah, Ehab
    CASE REPORTS IN HEMATOLOGY, 2018, 2018
  • [33] EXPERIENCE OF IBRUTINIB THERAPY IN THE TREATMENT OF PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Kurkina, N. V.
    Repina, E. A.
    Mashnina, N. N.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (01): : 55 - 56
  • [34] Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Shadman, Mazyar
    Karve, Sudeep
    Patel, Sima
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Srivastava, Bhavini P.
    Stephens, Deborah M.
    BLOOD, 2023, 142
  • [35] The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients
    Rhodes, Joanna
    Barr, Paul M.
    Ujjani, Chaitra S.
    Nabhan, Chadi
    Tam, Constantine S.
    Jacobs, Ryan
    Lansigan, Frederick
    Hill, Brian T.
    Brander, Danielle M.
    Shadman, Mazyar
    Skarbnik, Alan P.
    Pu, Jeffrey J.
    Sehgal, Alison R.
    Pagel, John M.
    Allan, John N.
    Kennard, Kaitlin
    Cheson, Bruce D.
    Beach, Douglas F.
    Patel, Bhavisha
    Isaac, Krista
    Tuncer, Hande H.
    Furman, Richard R.
    Mato, Anthony R.
    BLOOD, 2017, 130
  • [36] Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
    Yin, Qingsong
    Sivina, Mariela
    Robins, Harlan
    Yusko, Erik
    Vignali, Marissa
    O'Brien, Susan
    Keating, Michael J.
    Ferrajoli, Alessandra
    Estrov, Zeev
    Jain, Nitin
    Wierda, William G.
    Burger, Jan A.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (04): : 1740 - 1747
  • [37] Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
    Okamoto, Koh
    Proia, Laurie A.
    Demarais, Patricia L.
    CASE REPORTS IN INFECTIOUS DISEASES, 2016, 2016
  • [38] Ibrutinib for treatment of chronic lymphocytic leukemia
    Vela, Cory M.
    McBride, Ali
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (06) : 367 - 375
  • [39] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Deodato, Marina
    Frustaci, Anna Maria
    Zamprogna, Giulia
    Cairoli, Roberto
    Montillo, Marco
    Tedeschi, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (05) : 273 - 284
  • [40] Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
    Neffendorf, James E.
    Gout, Irina
    Hildebrand, G. Darius
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (13): : 1277 - 1277
12345